Ignacio Dolado

Roche announced today data from a five-year follow-up of the pivotal phase III POLARIX study evaluating Polivy® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with untreated diffuse large B-cell lymphoma (DLBCL). Data were presented in an oral session at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, 7-10 December 2024 in San Diego, US. This latest analysis conducted after a median follow-up of 60.9 months, includes descriptive data on primary and secondary endpoints, as well as safety results. “POLARIX was the first trial to elevate treatment standards for frontline diffuse large B-cell lymphoma in 20 years and we are additionally encouraged by the five-year follow-up results,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “More than 38,000 people worldwide have been treated with Polivy in combination with R-CHP and these data continue to underscore its potential to improve outcomes for people diagnosed with this aggressive lymphoma.” Follow-up exploratory analysis after five-years indicated a positive trend in overall survival (OS) in the intent-to-treat (ITT) population in favour of Polivy in combination with R-CHP compared to MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Results showed a trend in reduction in the risk of death (HR 0.85; 95% CI: 0.63–1.15) for people with previously untreated DLBCL with the Polivy combination, an improvement on the three-year follow-up data (HR 0.94; 95% CI: 0.67–1.33). The five-year analysis of POLARIX indicates that the full difference in OS between treatment arms has yet to be observed and an additional two years of follow-up will continue. “Diffuse large B-cell lymphoma is a notoriously challenging cancer to treat, however, Polivy in combination with R-CHP has shown to be a critical advance for patients by helping to reduce relapse and disease progression,” said Gilles Salles, MD, PhD, Chief of Lymphoma Service, Division of Hematological Malignancies, Memorial Sloan Kettering Cancer Center, US. “The survival trend seen in this follow-up analysis reinforces the potential impact of frontline treatment with Polivy in combination with R-CHP and its role as a standard of care therapy.” Polivy in combination with R-CHP is currently approved for the treatment of first-line (1L) DLBCL in more than 90 countries worldwide including the US, countries throughout the EU, the UK, Japan, Canada and China. Roche continues to work with health authorities around the world to bring this treatment regimen to even more patients. #clinicalstudy #POLARIX #lymphoma #DLBCL #Polivy #Genentech #Roche

268

Case Study in 60 seconds Its harder than you think…. Octapharma is one of the worlds largest plasma collection organizations. Plasma is a highly regulated asset requiring ongoing temperature monitoring. Thats hot….sorry Paris A global organization was monitoring temperature…..BY HAND! This leads to human error, asset loss, operational inefficiency and more. The solution - Checkit (LSE: CKT) Sensors and monitoring technology built to eliminate these challenges. Automated monitoring, real time notifications and alerts, security and reliability to monitor your assets even when worst case scenario hacks occur. https://lnkd.in/ecxUdxtP #sensors #temperaturemonitoring #plasma

29

1 Kommentar

🌟 Engage with us at the 58th Diabetes Congress! 🌟 At the 58th Diabetes Kongress, organized by the Deutsche Diabetes Gesellschaft (DDG), our team has a primary mission: to #raiseawareness for metabolic dysfunction-associated steatohepatitis (#MASH). MASH, often referred to as a 'silent disease', presents minimal symptoms, especially in its early stages. As the prevalence of obesity and type 2 diabetes continues to rise—both significant risk factors for MASH—the number of individuals affected by this chronic disease is increasing. Recognizing and diagnosing MASH can be challenging due to its non-specific symptoms, including abdominal and back pain, fatigue, and weakness. For individuals diagnosed with type 2 diabetes and obesity, the FIB-4 index serves as a potent tool for identifying those with a high risk of liver disease. Early diagnosis is crucial, as lifestyle adjustments like diet and exercise can sometimes effectively halt the progression of MASH and, in certain instances, even reverse early-stage liver damage. At Novo Nordisk, we are committed to addressing this issue by leveraging our expertise in obesity and type 2 diabetes. We invite you to engage in this critical dialogue and work together towards a better understanding and management of MASH. #DrivingChange #together #DK2024

136

1 Kommentar

Today, I have been part of the NextGen Obesity Panel discussion at the Sachs Associates Annual Biotech in Europe Forum in Basel, Switzerland. Key reflections from the discussion it that currently we are treating obesity as it is one disease. But it is not! Obesity is a complex multifactorial disease that involves the interplay between genes, epigenetics, metabolism, and behavior. Therefore, we need more tools in the toolbox of anti-obesity medications. The future of anti-obesity therapy should focus on the following: ❇️ Novel drug concepts: To harness the full weight loss potential of weight loss medications there is a need for novel drug concepts – either as novel stand-alone alternatives to incretins or as add-on therapies to improve weight loss efficacy and/or associated comorbidities (e.g. diabetes). There are many interesting combinations approaching. ❇️ Muscle mass preservation: With current weight loss strategies lean mass accounts for 20-40% of the weight lost. The next generation of anti-obesity therapy would ideally conserve or even ad muscle during weight loss! ❇️ Sustained body weight reduction: This is really the true “holy grail” of obesity pharmacology, can we prevent weight rebound after stop of current treatments! It is impressive how far the obesity field has moved within a decade with treatment options now providing clinically relevant weight loss. It is also clear that we are not done yet. It will be exciting to see where the next decade will take us!

212

4 Kommentare

🧡 Celebrating 5 Incredible Years at CSL Vifor Switzerland 🧡 I am thrilled to celebrate my 5th anniversary as Omnichannel Manager at CSL Vifor. These years have been marked by intense collaboration, innovative initiatives, and exciting projects for our customers and patients. 🤝 Teamwork: Working with such great people as well as with dedicated and talented team is an enriching experience. Together, we overcome numerous challenges and reach new heights. 🚀 Initiatives and Innovation: I'm lucky enough to be able to lead initiatives that not only improve our processes, but also stimulate our creativity and ability to innovate. 💃 Skill Development: These years have been a tremendous opportunity for personal and professional growth as well as for continuously developping new skills and deepening my knowledges. 💥  Exciting Projects: Participating in various and stimulating projects has been a true source of motivation. Each project brought its share of challenges and satisfactions. 🤩  Opportunities and Connections: I have had the chance to meet beautiful people and seize unique opportunities that have enriched my journey. 🙏 Support and Trust: A big thank you to my management for its constant support and trust. Its guidance has been essential to our success. I am excited to see what the future holds and to continue contributing to our collective success. Thank you to everyone who has been part of this journey! #Teamwork #Innovation #Leadership #CareerGrowth #Omnichannel

86

14 Kommentare

At Merck KGaA, Darmstadt, Germany, we're pushing the boundaries of what's possible with artificial intelligence, and my colleague Philipp Harbach is giving us a sneak peek into how we're advancing across the entire AI value chain. From revolutionizing semiconductor production to accelerating groundbreaking research, we're not just innovating materials and processes—we're also speeding up the discovery of new drugs. But here's the big question: Where do YOU think AI can make the biggest impact? Let's start a conversation—I'd love to hear your thoughts in the comments! 👇 #AI360View

2

Sharing a panel next to these large #pharmaceutical #companies in an event like #AUTOMAplus2024 from BGS Medical Events reveals that at Almirall we know what we do and we do it well, and we are clear that #evolution will be #digital or it will not be.

16

1 Kommentar

#News: Roche is starting off 2025 just as it did 2024: with a trip to #China for a new #antibodydrugconjugate deal. This time, the Swiss pharma is ringing in the New Year with Innovent in a licensing pact worth up to $1 billion. The partners will work on #IBI3009, a DLL3-targeted #ADC that has been cleared for #clinicaltrials in the U.S. and China. The first patient with #smallcelllungcancer was dosed in a #PhaseI trial in December 2024. #Roche will receive exclusive rights to develop, manufacture and commercialize IBI3009. Both companies will work on early-stage development of the asset before Roche takes over full development, according to Wednesday’s release. The deal involves an $80 million upfront fee, and $1 billion possible in milestones later on, plus royalties on net sales. The therapy could be a rival to Amgen ’s #Imdelltra, which was approved in May 2024 for #smallcell #lungcancer. Read more from BioSpace using the link in the comments. #HappyNewYear! #RSKJan25

3

1 Kommentar

Lung cancer is the leading cause of cancer-related mortality worldwide with an estimated 2.5 million people diagnosed each year. Having spent a considerable amount of my career working in oncology, and specifically lung cancer, I am proud to be part of the movement that makes significant progress on this sobering statistic. With November being Lung Cancer Awareness Month, my hope is that we take time to acknowledge those who have lost their lives to lung cancer, those currently living with, and fighting, lung cancer, their families and friends, as well as those who spend day in and out on the front lines in the pursuit of discovering “what’s next.” As an industry, and as a lung cancer community, we have made incredible strides in the prevention, screening, intervention, and treatment of lung cancer. These advances should be celebrated, while at the same time fueling our continued commitment and collaboration. Equitable access to screening and treatments, new approaches to get in front of cancer, and policies that support these are mission critical. Personally, I am steadfast in my commitment, and I am proud of my colleagues and team at Johnson & Johnson who are working hard to realize our bold vision to eliminate cancer. Public private partnerships like IDERHA (Integration of heterogenous Data and Evidence towards Regulatory & HTA Acceptance) that are looking to maximise data and technology to transform lung cancer diagnosis, care, and ultimately patient outcomes, are certainly part of the solution and future. #MyCompany and #LungCancerAwarenessMonth 

64

Great speaking with Florence Vuichard and Pascal Michel for a story in today's "Schweiz am Wochenende". We talked about medicines people urgently need and sometimes cannot get, because current supplies are in different pack sizes than prescribed or because they are warehoused in different countries from which they cannot be imported due to regulatory hurdles. In my view there would be an easy solution: liberalilze the pharmaceutical supply chain accross borders and agree on prices that reflect the true value of essential generic medicines. We also spoke about the medicines everybody wants but nobody can produce enough of: weight-loss drugs. While this is a unique market situation like I have never seen before, we also need address rising environmental concerns with a dramatically growing number of one-time application devices.

254

10 Kommentare

Want a sneak peak of the skill-building portal inside Beyond the Ceiling? This is my 4 month group coaching program exclusively for women in Pharma/Biotech who want to: ✅ get clarity on your next best career move ✅ get a new job or promotion ✅ build your career and leadership skills to be confident, seen and respected in your field There are 2 live coaching calls each week to get personalized guidance and coaching plus the Career Coach Hotline to get on-demand coaching between calls. I guide you every step of the way to meet your career goals. To join when enrollment opens Tuesday - July 23: 1️⃣ Submit your application at https://lnkd.in/eyiveidj 2️⃣ If approved, secure your spot by making your payment ($5,000 or 4 monthly payments) 3️⃣ Get immediate access to the skill-building portal so you can get results right away before we start Aug 23. (Giving you a full extra month in the program!) Enrollment is only open for 2 weeks. The sooner you apply, the more bonus time you get in the program. You don’t need to struggle with your career. Be ready to apply. P.S. Have a question about the program? Check out the 🔗 above or send me a message with your question. #careerdevelopment #womeninpharma #womeninbio #pharma #biotech #lifesciences

3

It’s time to enter a new dimension of mass spectrometry, enabling more people than ever to benefit from this incredible innovation. Curious to learn more about how we’re making this a reality? Check out the articles I’ve shared here on LinkedIn or visit: https://lnkd.in/dqZvqNTp. #MassSpectrometry #MassSpec #Intergrateddiagnostics #Healthcare #Diagnostics #Research #diagnostics #PrecisionDiagnostics #Earlydiagnostics #ValueofDiagnostics

19

💊 Your Path to a Pharma Career in Switzerland 🇨🇭 Switzerland is a global hub for biotech and pharma, offering incredible opportunities for career growth. Whether you’re a seasoned professional or just starting out, understanding the Swiss job market and its nuances is key. I’ve shared tips and insights to help you make the move—check out my latest blog: https://lnkd.in/eeKdvBcS I’ve also added a new section on my site about Moving to Switzerland and Swiss Biotech/Pharma to help answer common questions—bookmark this for more: https://lnkd.in/epUj7XyT #PharmaCareers #Biotech #Switzerland #CareerGrowth #SwissLife #MovingToSwitzerland #ExpatLife

8

Have you ever heard of Acromegaly? Do you know anyone with this condition? Acromegaly is a chronic, rare disease related to excessive production of growth hormone, with 9 out of 10 cases originating from a monoclonal benign pituitary tumor. What do patients experience? Patients can show progressive disfigurement primarily of the face and extremities. Sadly, it is often diagnosed late, in middle-age adults, due to it’s subtle progression, causing a variety of cardiovascular, respiratory, metabolic, musculoskeletal, neurological, and neoplastic comorbidities that might not be reversible with treatments that work to control the disease. At Debiopharm we are exploring how we can improve the quality of life and treatment convenience of people living with this condition. Today, on Acromegly Awarness Day, I invite you to learn more through the inspiring patient organization, Acromegaly Community. #rarediseases #acromegaly #clinicalresearch  https://lnkd.in/egH3873S

24

1 Kommentar

𝗥𝗲𝗳𝗹𝗲𝗰𝘁𝗶𝗻𝗴 𝗼𝗻 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲𝘀 𝗶𝗻 𝗛𝗲𝗽𝗮𝘁𝗼𝗹𝗼𝗴𝘆, 𝗚𝗮𝘀𝘁𝗿𝗼𝗲𝗻𝘁𝗲𝗿𝗼𝗹𝗼𝗴𝘆 & 𝗚𝗜 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 As Thanksgiving approaches, I find myself reflecting on the incredible journey of scientific discovery and collaboration in 𝘏𝘦𝘱𝘢𝘵𝘰𝘭𝘰𝘨𝘺 𝘢𝘯𝘥 𝘎𝘢𝘴𝘵𝘳𝘰𝘦𝘯𝘵𝘦𝘳𝘰𝘭𝘰𝘨𝘺 TA. It's a privilege to have been part of this evolving narrative, alongside brilliant KOLs and the transformative innovations that took place in Preventive Medicine, Screening, and Drug Development. It all began with the landmark paper by El-Serag and Mason in 1999 in 𝘕𝘦𝘸 𝘌𝘯𝘨𝘭𝘢𝘯𝘥 𝘑𝘰𝘶𝘳𝘯𝘢𝘭 𝘰𝘧 𝘔𝘦𝘥𝘪𝘤𝘪𝘯𝘦, which first highlighted the increasing incidence of hepatocellular carcinoma (HCC). Inspired by their work, I published my own study in the 𝘉𝘳𝘪𝘵𝘪𝘴𝘩 𝘑𝘰𝘶𝘳𝘯𝘢𝘭 𝘰𝘧 𝘊𝘢𝘯𝘤𝘦𝘳, analyzing global trends in HCC. Years later, I had the honor of co-authoring paper with the same renowned KOL, showing that HCC trends are, in fact, on the decline…. a significant milestone published in 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘎𝘢𝘴𝘵𝘳𝘰𝘦𝘯𝘵𝘦𝘳𝘰𝘭𝘰𝘨𝘺 𝘢𝘯𝘥 𝘏𝘦𝘱𝘢𝘵𝘰𝘭𝘰𝘨𝘺. This journey reminds me of the impact of cross-discipline collaborations in improving patient outcomes. I am deeply grateful to these exceptional KOLs, and industry leaders who make these advances possible. This Thanksgiving, I am thankful for the opportunity to contribute to this meaningful work and for the collective efforts that drive us closer to a healthier future in the U.S. #Hepatology #Gastroenterology #Thanksgiving #Collaboration #PreventiveMedicine #Innovation #MSL #MedicalAffairs #Gratitude #MedicalScienceLiaison

11

Roche announced today positive topline results of the phase III CENTERSTONE study of Xofluza® (baloxavir marboxil), an antiviral, showing a reduction in the transmission of influenza viruses. The study met its primary endpoint, demonstrating that a single, oral dose of Xofluza taken by people infected with influenza significantly reduced the likelihood of others in their household contracting the virus. Xofluza was well tolerated with no new safety signals identified. 👉 Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members. 👉 This is the first time that any antiviral used in the treatment of a respiratory viral illness has demonstrated a transmission reduction benefit in a global phase III study. 👉 Reducing the spread of infection in the household could help limit transmission within communities and societies, easing the burden of both seasonal and pandemic influenza on healthcare systems. CENTERSTONE is the first global phase III study to show a transmission reduction benefit with an antiviral used in the treatment of a respiratory viral illness. This new data may add to the benefits of Xofluza, which is currently approved for treating symptoms and preventing infection following virus exposure. The topline results will be presented at the 2024 OPTIONS XII for the Control of Influenza congress (29 September - 2 October, Brisbane, Australia). “Building on Xofluza’s established efficacy in treating and preventing influenza after exposure, this new evidence of transmission reduction represents an important advance that could help improve health outcomes at an individual and community level,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We look forward to discussing these data with regulatory authorities and public health organisations for influenza pandemic preparedness to bring these benefits to patients.” Influenza is one of the most common yet serious infectious diseases, representing a significant burden to public health. Every year, seasonal influenza infects an estimated one billion people and causes millions of hospitalisations and up to 650,000 deaths globally. With the co-circulation and burden of multiple respiratory viruses (including COVID-19) infecting individuals within and outside of the winter season, it is more important than ever that influenza is not underestimated. For the effective control of both seasonal and pandemic influenza, early diagnosis and treatment is critical. #publichealth #infectiousdiseases #respiratoryviruses #influenza  #clinicalstudy #Xofluza #Roche

144

1 Kommentar

2023 was a big year for Grünenthal! Our latest annual report is now available, providing insight into our exciting journey and transformative vision. 🚀 At Grünenthal, we touch the lives of millions of patients worldwide with innovative treatments that can give them the quality of life they deserve. We are striving to achieve our vision of a #WorldFreeofPain by pursuing two key strategic approaches. First, we are targeting organic growth by focusing our R&D activities on pain management. Second, we are tapping into inorganic growth by acquiring assets that strengthen our established medicine portfolio – no matter which therapeutic area. These deals significantly boost our profitability, which enables us to continue investing in pain innovation. Our latest joint venture collaboration with Kyowa Kyrin International gives Grünenthal access to 13 life-changing brands across six therapeutic areas. That makes it an excellent fit for our business and empowers us to reach even more patients around the globe. Learn more about our joint venture Grünenthal Meds and why we might be the right partner for you too, in our latest Grünenthal Report: https://lnkd.in/eMUhjaiy #WorldFreeofPain #WeAreGrünenthal

69

1 Kommentar

Navigating life with any health condition can be challenging. For the ~500,000 people in Switzerland affected by rare diseases, these challenges are often exacerbated due to the rarity of their conditions and the often veiled presentation of symptoms. This November, the @Rare Disease Action Forum (RDAF) will be hosting the @Swiss Rare Disease Summit, in partnership with Alexion Pharmaceuticals, Inc. and Takeda. It brings an opportunity for collaboration across the rare disease space, vital to identifying areas to advance our healthcare system and improve outcomes for rare disease patients. It is our responsibility, as an industry, to take action and support those with rare diseases so they can access the best care—from early diagnosis through to the most effective treatment and care plans—so they can live their lives to the full. Learn more about the summit here: https://lnkd.in/e_-hDNYf #SwissRareDiseaseSummit #RareDiseases #Switzerland #RDScreening #EarlyDiagnosis

38

1 Kommentar